Edition:
India

Ranbaxy Laboratories Ltd (RANB.NS)

RANB.NS on National Stock Exchange of India

859.80INR
1 Apr 2015
Change (% chg)

-- (--)
Prev Close
Rs859.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
Rs869.70
52-wk Low
Rs790.10

RANB.NS

Chart for RANB.NS

About

Ranbaxy Laboratories Limited (Ranbaxy) is a research-based international pharmaceutical company serving customers in over 150 countries. The Company develops, manufactures and markets generic, branded generic, value-added and over-the-counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and... (more)

Overall

Beta: 0.09
Market Cap(Mil.): Rs373,003.41
Shares Outstanding(Mil.): 425.66
Dividend: --
Yield (%): --

Financials

  RANB.NS Industry Sector
P/E (TTM): -- 29.13 29.87
EPS (TTM): -19.13 -- --
ROI: -- 15.56 14.95
ROE: -- 16.69 16.29

U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial

Nov 21 A U.S. appeals court upheld AstraZeneca Plc and Ranbaxy Laboratories' victory in a lawsuit accusing them of reaching an illegal deal to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium.

22 Nov 2016

BRIEF-Sun Pharmaceutical Industries on track to achieve benefits from Ranbaxy acquisition

* Sun Pharmaceutical Industries Ltd says synergies from the Ranbaxy acquisition are gaining momentum and co on track to achieve the targeted benefits

10 Nov 2016

EU court to rule on drugmaker Lundbeck's pay-for-delay deals

BRUSSELS, Sept 6 Europe's top court will rule on Thursday whether Danish drugmaker Lundbeck breached EU antitrust rules by paying smaller rivals to delay generic copies of its blockbuster citalopram anti-depressant from entering the market.

06 Sep 2016

Earnings vs. Estimates